Fusion Genomics is advancing ONETest™, an on-site targeted metagenomic platform designed to help close diagnostic gaps in life-threatening infections and support accredited hospital laboratories moving from Dx to Rx in less than 24 hours.
This overview is intended to orient qualified investors to the clinical problem, platform strategy, validation evidence, and commercial direction behind Fusion Genomics.
Current methods can be slow, narrow, or operationally difficult to deploy inside hospital laboratories.
ONETest™ combines QuantumProbes™, automation, UniPrep™, sequencing, and FusionCloud™ Actionable Intelligence.
Fusion is focused on hospital-centered deployment, validation partnerships, and scalable implementation workflows.
Critical-care teams often need broad pathogen detection inside the treatment window, but conventional diagnostics and send-out testing can leave patients without actionable microbiology when it matters most.
In key high-acuity indications, a substantial fraction of suspected infections can remain unresolved using current standard methods.
Delayed or missed infection diagnosis creates significant direct hospital cost burden through prolonged care, uncertainty, and empiric treatment.
Culture and send-out workflows may not return actionable answers within the critical-care decision window.
Hospitals already understand the value of faster, broader infectious-disease answers. The challenge is making metagenomics operationally practical, economically viable, and interpretable within hospital laboratory workflows.
Empiric therapy remains common when conventional methods do not identify the causal organism quickly enough.
Panel-based testing can miss unexpected, emerging, or off-panel organisms in complex hospital samples.
Send-out models can be expensive, slower, and less aligned with hospital operational economics.
Metagenomics needs background-aware, organism-specific interpretation rather than undifferentiated organism lists.
ONETest™ is not a single assay component. It is an integrated platform stack spanning enrichment chemistry, library preparation, automation, sequencing workflow, and software interpretation.
Probe-based enrichment designed to increase microbial signal while preserving broad pathogen context.
Walk-away workflow design supports reproducibility and reduces implementation burden for hospital labs.
Library chemistry designed to convert captured DNA into sequencing-ready outputs.
Actionable Intelligence for relevance ranking, AMR-marker context, and interpretation support.
Fusion’s investor narrative is anchored in clinical validation data, platform development across diverse sample types, and hospital-centered implementation work.
ONETest™ PathoGenome has been evaluated across a lower-respiratory BAL validation study focused on pathogen detection in hospital-relevant samples.
Reported clinical agreement with standard-of-care culture testing in the BAL validation narrative.
Fusion’s broader platform history includes clinical, respiratory, environmental, and surveillance sample types.
Fusion is advancing a hub-to-in-house implementation strategy with hospital partners and qualified laboratory workflows.
Fusion’s commercialization model is designed to reduce adoption friction: educate the clinical users, enable hub-based experience, and support in-house conversion where institutional validation and operational fit are established.
Engage infectious disease, ICU, transplant, oncology, and respirology champions around unresolved diagnostic gaps.
Allow institutions to gain experience through validated hub workflows before committing to in-house adoption.
Support hospitals moving toward internal implementation where volume, validation, infrastructure, and economics align.
Lower-respiratory infections provide the initial focus, with future menu expansion opportunities across bloodstream, CNS, and sterile-site infections where supported by appropriate validation.
Investor materials, detailed validation data, financial model, and supporting diligence documents are not publicly downloadable from this website and may be provided only to qualified investors following appropriate review.
This page may contain forward-looking statements, estimates, and projections. Please review Fusion Genomics’ Legal & Regulatory Notices.